Toggle Main Menu Toggle Search

ePrints

Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR

Lookup NU author(s): Professor Ruth Plummer, Dr Louise Li, Rebecca Perrett, Professor Alan Calvert

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Publication metadata

Author(s): Plummer ER, Vidal L, Li L, Shaw H, Perrett RH, Shahidi M, Amelsberg A, Temple G, Calvert AH, de Bono J

Publication type: Article

Journal: European Journal of Cancer Supplements

Year: 2006

Volume: 4

Issue: 12

Pages: 173-174

ISSN (print): 1359-6349

URL: http://dx.doi.org/10.1016/S1359-6349(06)70578-X

DOI: 10.1016/S1359-6349(06)70578-X

Notes: From conference: 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 573 Poster.


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share